全文获取类型
收费全文 | 99765篇 |
免费 | 6942篇 |
国内免费 | 322篇 |
专业分类
耳鼻咽喉 | 1274篇 |
儿科学 | 2534篇 |
妇产科学 | 2306篇 |
基础医学 | 12437篇 |
口腔科学 | 2061篇 |
临床医学 | 9740篇 |
内科学 | 21742篇 |
皮肤病学 | 1065篇 |
神经病学 | 8652篇 |
特种医学 | 3357篇 |
外国民族医学 | 3篇 |
外科学 | 16223篇 |
综合类 | 1401篇 |
现状与发展 | 1篇 |
一般理论 | 75篇 |
预防医学 | 7883篇 |
眼科学 | 2649篇 |
药学 | 6340篇 |
中国医学 | 142篇 |
肿瘤学 | 7144篇 |
出版年
2023年 | 401篇 |
2022年 | 692篇 |
2021年 | 1646篇 |
2020年 | 880篇 |
2019年 | 1586篇 |
2018年 | 1903篇 |
2017年 | 1399篇 |
2016年 | 1552篇 |
2015年 | 1834篇 |
2014年 | 2726篇 |
2013年 | 4318篇 |
2012年 | 6185篇 |
2011年 | 6454篇 |
2010年 | 3618篇 |
2009年 | 3343篇 |
2008年 | 6123篇 |
2007年 | 6815篇 |
2006年 | 6512篇 |
2005年 | 6661篇 |
2004年 | 6495篇 |
2003年 | 6113篇 |
2002年 | 6103篇 |
2001年 | 782篇 |
2000年 | 538篇 |
1999年 | 764篇 |
1998年 | 1281篇 |
1997年 | 1137篇 |
1996年 | 960篇 |
1995年 | 964篇 |
1994年 | 844篇 |
1993年 | 741篇 |
1992年 | 562篇 |
1991年 | 510篇 |
1990年 | 445篇 |
1989年 | 461篇 |
1988年 | 433篇 |
1987年 | 449篇 |
1986年 | 443篇 |
1985年 | 496篇 |
1984年 | 706篇 |
1983年 | 754篇 |
1982年 | 977篇 |
1981年 | 915篇 |
1980年 | 866篇 |
1979年 | 447篇 |
1978年 | 529篇 |
1977年 | 579篇 |
1976年 | 490篇 |
1975年 | 428篇 |
1974年 | 339篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
91.
92.
Varsha Patki Joe Virbasius William S. Lane Ban-Hock Toh Howard S. Shpetner Silvia Corvera 《Proceedings of the National Academy of Sciences of the United States of America》1997,94(14):7326-7330
Phosphatidylinositol 3-kinases (PI 3-kinases) have been implicated in membrane trafficking in the secretory and endocytic pathways of yeast and mammalian cells, but the molecular mechanisms by which these lipid kinases operate are not known. Here we identify a protein of 170 kDa that is rapidly released from cell membranes in response to wortmannin, a potent inhibitor of mammalian PI 3-kinases. The amino acid sequence of peptides from p170 reveal its identity to early endosomal antigen (EEA) 1, an endosomal antigen with homology to several yeast proteins genetically implicated in membrane trafficking. Immunofluorescence analysis of 3T3-L1 adipocytes with antisera against p170/EEA1 reveal a punctate peripheral pattern that becomes diffuse in response to wortmannin. In vitro, p170/EEA1 binds specifically to liposomes containing PIns(3)P, suggesting that the effect of wortmannin on cells is due to inhibition of PIns(3)P production. Thus, p170/EEA1 may define a family of proteins that mediate the regulatory effects of 3′-phosphoinositides on membrane trafficking in yeast and mammalian cells. 相似文献
93.
William M. Chadduck Duc H. Duong John M. Kast David J. Donahue 《Child's nervous system》1995,11(10):579-583
Cerebellar hemorrhage is a devastating condition with morbidity and mortality related not only to the etiology of the hemorrhage, but also to the timing of the intervention. Sixteen consecutive pediatric patients with acute cerebellar hemorrhages are presented: 6 had vascular abnormalities, 3 had tumors, and 2 had hemorrhages of unknown etiology. Thirteen of the 16 patients survived with only 1 of the 13 having persistent vegetative state as a neurologic outcome. Six of 8 patients presenting in a moribund condition had good outcomes, and 3 of 4 patients presenting with fixed and dilated pupils also had good outcomes. Thus, in contrast to adults, rapid evaluation by CT scanning, followed by the judicious use of ventricular drainage and prompt surgical treatment, have resulted in favorable outcomes in pediatric patients despite their poor clinical presentations. None of the neonates having cerebellar hemorrhages required surgical intervention; their courses could be followed clinically and with transfontanel ultrasound.Presented as a poster at the 14th Congress of the European Society for Paediatric Neurosurgery, Lyon, France, 21–23 September 1994, and the XXII Annual Meeting of the International Society for Pediatric Neurosurgery, Birmingham, UK, 25–28 September 1994 相似文献
94.
Sintov Amnon Scott William A. Gallagher Kim P. Levy Robert J. 《Pharmaceutical research》1990,7(1):28-33
Epicardial antiarrhythmic drug administration was studied as a therapeutic approach for experimental ventricular tachycardia (VT) in an open-chest dog model. Lidocaine-polyurethane matrices (28%, w/w) were formulated as a model system. Matrices were placed on the left ventricular epicardium in each of 23 anesthetized open-chest dogs with ouabain-induced VT, to evaluate effectiveness in restoring sinus rhythm. Conversion occurred in all animals treated with matrices containing 300 mg or more of lidocaine after 1.5 to 7.0 min. The matrix lidocaine content correlated linearly with the time required for conversion to sinus rhythm (r = 0.75, P = 0.0002); irrespective of matrix size the myocardial/plasma lidocaine ratio was 20.1 ± 4.2 (mean ± SD) at the time of conversion. In a separate series of five dogs without ventricular tachycardia, systolic wall thickening measured with sonomicrometers after 5 min of controlled-release lidocaine administration (500- to 1000-mg matrix lidocaine content, 7.48 ± 3.49-mg/kg dose) was only minimally diminished (–14.1%) and this effect was observed only at the site of matrix placement on the anterior-apical epicardium. In contrast, intracoronary injection of 0.3 or 1.0 mg/kg of lidocaine-HCl resulted in complete elimination of wall thickening or replacement by systolic thinning. Thus epicardial administration of lidocaine from polyurethane matrices was an effective means of treating ouabain-induced ventricular tachycardia. Regional myocardial function in the vicinity of the matrices was modified to a very limited degree, supporting the view that the matrices can be used safely, without serious risk to ventricular contractile performance. 相似文献
95.
96.
Identifying patients at risk for,and treatment of major psychiatric complications of cancer 总被引:3,自引:0,他引:3
William Breitbart 《Supportive care in cancer》1995,3(1):45-60
A critically important aspect of supportive care in cancer is the prompt recognition and effective treatment of psychiatric complications. Psychiatric disorders such as depression, anxiety and delirium occur in a signifcant percentage of cancer patients, particularly as disease advances and as cancer treatments become more aggressive. This paper reviews factors that can be utilized to identify patients who are at increased risk for developing psychiatric complications, such as those with advanced disease, certain cancer treatments, uncontrolled physical symptoms, functional limitations, lack of social support, and past history of psychiatric disorder. Methods of diagnostic assessment and strategies for managing depression, anxiety, delirium and suicidal ideation are also reviewed.Presented as an invited lecture at the 6th International Symposium: Supportive Care in Cancer, New Orleans, La., USA, 2–5 March 1994 相似文献
97.
Pharmaceutical Research - 相似文献
98.
99.
Dr. Andrew G. Bostom M.D. Dr. Anne L. Hume Pharm.D. Dr. Charles B. Eaton M.D. Dr. Joseph P. Laurino Ph.D. Ms. Lisa R. Yanek B.A. Ms. Mary S. Regan B.S. Mr. William H. McQuade M.P.H. Dr. Wendy Y. Craig Ph.D. Ms. Gayle Perrone M.B.A. Dr. Paul F. Jacques Sc.D. 《Pharmacotherapy》1995,15(4):458-464
Study Objective . To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design . Randomized, double-blind, placebo-controlled trial. Setting . Outpatient clinic. Patients . Forty-four patients with documented premature CHD. defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. Interventions . Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results . High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dl; p<0.001). Multiple linear regression analysis revealed no significant effect of supplementation on postintervention Lp(a) levels (p=0.39) in a model that included treatment group assignment, and baseline Lp(a) levels. Conclusions . Our findings do not support a clinically important lowering effect of high-dose ascorbate on plasma Lp(a) in patients with premature CHD. 相似文献
100.
Choc Miles G. Hsuan Francis Honigfeld Gilbert Robinson William T. Ereshefsky Larry Crismon Miles L. Saklad Stephen R. Hirschowitz Jack Wagner Richard 《Pharmaceutical research》1990,7(4):347-351
Clozapine plasma levels were monitored in 16 patients during a series of three consecutive treatments (single dose-multiple dose-single dose). Each patient received a single 75-mg dose (3 x 25 mg) with clozapine tablets, and serial plasma samples were collected over 48 hr after the dose. At 48 hr, a multiple-dose regimen was started, consisting of an initial dose escalation period followed by dosing at a constant regimen for at least 6 days. After the last dose, serial plasma samples were again obtained over 72 hr. Drug was then withheld for at least 7 days, a final single 75-mg dose was given, and plasma sampling was repeated. A subset of the patient population (N = 7) was used to test for a food effect during the single-dose treatments. The pharmacokinetic parameters between the initial and the final single dose periods were not significantly different. Similarly, there were no differences within patients when given the dose after fasting (fed 1 hr after dose) or with a meal. In contrast, the terminal elimination rate differed between the single-dose and the multiple-dose treatments (t1/2 m3 = 7.9 hr single dose and 14.2 hr multiple dose) (P less than 0.05) and the dose-normalized area under the plasma concentration/time curves increased 27% with multiple dosing. Since a previous study in patients (Choc et al., Pharm. Res. 4:402-405, 1987) showed dose proportionality of clozapine plasma concentrations during multiple-dose regimens, the present results cannot be described by Michaelis-Menten kinetics. 相似文献